Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency

Stopped early · Phase 2

Conditions studied: Heart Failure

In brief

The purpose for this study (CY 1124) is to evaluate the effects of CK-1827452, a cardiac myosin activator, on myocardial systolic performance, myocardial oxygen consumption, and myocardial efficiency in patients with heart failure and to confirm that the unique preclinical pharmacological profile of CK- 1827452 is substantially the same in patients with heart failure.

Key facts

Study ID

NCT00748579

Run by

Cytokinetics

People needed

2

Starts

2008-09-01

Expected to finish

2009-07-01

Last updated by the study team

2020-01-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical indication for left and right heart catheterization
• Willing and able to provide informed consent
• Male or female 18 years of age or greater
• Symptomatic heart failure (≥ NYHA Class II)
• Ejection fraction ≤ 35%
• Patient is in sinus rhythm
• Patient is considered to be in suitable health in the opinion of the investigator, as determined by:
• o A pre-study physical examination with no clinical abnormalities which in the opinion of the investigator would preclude participation in the study other than physical symptoms or signs consistent with stable heart failure
• For female patients only: Post-menopausal or sterilized, or if she is of childbearing potential, she is not breastfeeding, her pregnancy test is negative, she has no intention to become pregnant for up to 90 days following the study, and she is using contraceptive drugs or devices

You may not qualify if…

• Acute myocarditis
• Hypertrophic, restrictive, or constrictive cardiomyopathy
• Congenital heart disease
• Known left ventricular thrombus
• Significant stenotic valvular disease (severe aortic stenosis, mitral stenosis)
• Poorly controlled hypertension (SBP > 180 mmHg)
• Pacemaker dependent ventricular rhythm
• Detectable troponin or CK-MB > ULN at any timepoint within 14 days of enrollment
• Acute coronary syndrome or revascularization procedure within 30 days of enrollment
• ≥ 50% stenosis of the left main coronary artery
• Plan for immediate revascularization procedure (PCI or CABG)
• GFR ≤ 35 ml/min/1.73 m2 by Modification of Diet in Renal Disease (MDRD) Equation or need for renal replacement therapy
• Known hepatic impairment (total bilirubin > 3 mg/dL, or ALT and AST > 2 times the upper limit of normal)
• Has received an investigational drug or device within 30 days before enrollment
• Has had any prior treatment with CK-1827452

Where it is running

• Johns Hopkins Medical Institutions — Baltimore, Maryland, United States
• UUHSC / Division of Cardiology — Salt Lake City, Utah, United States
• Mount Sinai Hospital — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.